This study provides preliminary data for the inclusion of pre-18F-DCFPyL PET/CT scan PSA values, original Gleason score, and presence of definitive sites of prostate cancer (PSMA-RADS-4/5) in the decision algorithm when deciding on further management for prostate cancer patients with PSMA-RADS-3A lesions. This evidence concerns the gene FOLH1 and prostate cancer.